BCG: the challenge continues

Scandinavian Journal of Infectious Diseases
P E Fine

Abstract

It is widely recognized that BCG provides inconsistent and often inadequate protection against tuberculosis; however, simple estimates of efficacy fail to reflect the complexity of protection within, let alone between, populations. A decline in protection with an increase in age at vaccination has been seen in many studies. This may reflect 2 things: (i) that as people age they are exposed to a variety of mycobacterial challenges which may interfere with, or mask, the protection of BCG; and/or (ii) that the vaccine is better at protecting against primary disease than against either reactivation- or reinfection-type disease. These factors need to be taken into consideration when interpreting the results obtained with screening vaccines in animal models, as most of these models mimic acute primary-type disease. In addition, we have no evidence that the protection induced by BCG lasts for > 15 y, in any population. Recent data from South India indicate a complex interaction of age and time effects: BCG imparted consistent protection in children, but no protection for subjects > 15 y old, and may even have imparted negative protection among these older individuals. If true, these findings have important implications for efforts to ...Continue Reading

References

Jun 1, 1994·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·V H Springett, I Sutherland

❮ Previous
Next ❯

Citations

Jul 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Hans-Willi MittrückerStefan H E Kaufmann
Dec 8, 2006·The Journal of Infectious Diseases·Dan HuangZheng W Chen
Aug 30, 2007·The Journal of Infectious Diseases·B J MaraisN Beyers
Apr 15, 2006·Clinical Microbiology Reviews·D M ScollardD L Williams
Mar 23, 2006·Infection and Immunity·Liana TsenovaGilla Kaplan
Jan 1, 2011·Tuberculosis Research and Treatment·Grace E Marx, Edward D Chan
Feb 18, 2006·American Journal of Respiratory and Critical Care Medicine·Ben J MaraisJeff R Starke
Oct 27, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic SocietyUNKNOWN Infectious Diseases Society of America
Apr 22, 2009·PLoS Pathogens·Crystal Y ChenZheng W Chen
Nov 1, 2006·Emerging Infectious Diseases·Martine DebackerMichèle Dramaix
Jul 14, 2010·Journal of Biomedicine & Biotechnology·Guglielmo LuccheseDarja Kanduc
Oct 24, 2014·Immunotherapy·Gil Reynolds Diogo, Rajko Reljic
Sep 1, 2004·Expert Opinion on Biological Therapy·Michael J BrennanChristine F Sizemore
Sep 14, 2007·Immunological Reviews·William R Berrington, Thomas R Hawn
Sep 13, 2006·Parasite Immunology·D EliasS Britton
Dec 6, 2012·Tuberculosis Research and Treatment·Wu LiYujiong Wang
Jun 23, 2009·Expert Review of Vaccines·James A Triccas, Jonathan K Nambiar
Jan 30, 2010·Expert Review of Vaccines·Corinne S C MerleLaura C Rodrigues
Aug 4, 2004·The Lancet Infectious Diseases·S K ObaroK Luzuriaga
Sep 27, 2005·The Lancet Infectious Diseases·Chen-Yuan Chiang, Lee W Riley
Jul 9, 2008·The Journal of Dermatological Treatment·Kornelija MiseJakica Karanovic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.